company background image
SGRY

Surgery PartnersNasdaqGS:SGRY Stock Report

Market Cap

US$3.8b

7D

-9.6%

1Y

69.4%

Updated

26 Nov, 2021

Data

Company Financials +
SGRY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

SGRY Stock Overview

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States.

Surgery Partners Competitors

HCA Healthcare

NYSE:HCA

US$71.8b

Universal Health Services

NYSE:UHS

US$10.0b

Tenet Healthcare

NYSE:THC

US$8.1b

Encompass Health

NYSE:EHC

US$6.1b

Price History & Performance

Summary of all time highs, changes and price drops for Surgery Partners
Historical stock prices
Current Share PriceUS$43.74
52 Week HighUS$69.58
52 Week LowUS$24.20
Beta3
1 Month Change9.16%
3 Month Change-8.53%
1 Year Change69.40%
3 Year Change204.81%
5 Year Change212.43%
Change since IPO137.33%

Recent News & Updates

Oct 04
Estimating The Fair Value Of Surgery Partners, Inc. (NASDAQ:SGRY)

Estimating The Fair Value Of Surgery Partners, Inc. (NASDAQ:SGRY)

In this article we are going to estimate the intrinsic value of Surgery Partners, Inc. ( NASDAQ:SGRY ) by taking the...

Shareholder Returns

SGRYUS HealthcareUS Market
7D-9.6%-1.5%-2.7%
1Y69.4%19.1%21.3%

Return vs Industry: SGRY exceeded the US Healthcare industry which returned 19.1% over the past year.

Return vs Market: SGRY exceeded the US Market which returned 21.3% over the past year.

Price Volatility

Is SGRY's price volatile compared to industry and market?
SGRY volatility
SGRY Average Weekly Movement8.2%
Healthcare Industry Average Movement6.3%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: SGRY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: SGRY's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20049,950J. Evanshttps://www.surgerypartners.com

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through Surgical Facility Services and Ancillary Services segments. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.

Surgery Partners Fundamentals Summary

How do Surgery Partners's earnings and revenue compare to its market cap?
SGRY fundamental statistics
Market CapUS$3.84b
Earnings (TTM)-US$85.90m
Revenue (TTM)US$2.16b

1.8x

P/S Ratio

-44.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SGRY income statement (TTM)
RevenueUS$2.16b
Cost of RevenueUS$1.68b
Gross ProfitUS$479.70m
ExpensesUS$565.60m
Earnings-US$85.90m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.98
Gross Margin22.18%
Net Profit Margin-3.97%
Debt/Equity Ratio141.7%

How did SGRY perform over the long term?

See historical performance and comparison

Valuation

Is Surgery Partners undervalued compared to its fair value and its price relative to the market?

5.08x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: SGRY ($43.74) is trading above our estimate of fair value ($40.03)

Significantly Below Fair Value: SGRY is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SGRY is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: SGRY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SGRY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SGRY is overvalued based on its PB Ratio (5.1x) compared to the US Healthcare industry average (2.9x).


Future Growth

How is Surgery Partners forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

69.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: SGRY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SGRY's is expected to become profitable in the next 3 years.

Revenue vs Market: SGRY's revenue (9.9% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: SGRY's revenue (9.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SGRY's Return on Equity is forecast to be low in 3 years time (1.7%).


Past Performance

How has Surgery Partners performed over the past 5 years?

-26.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SGRY is currently unprofitable.

Growing Profit Margin: SGRY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SGRY is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare SGRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGRY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (32.5%).


Return on Equity

High ROE: SGRY has a negative Return on Equity (4.06%), as it is currently unprofitable.


Financial Health

How is Surgery Partners's financial position?


Financial Position Analysis

Short Term Liabilities: SGRY's short term assets ($841.7M) exceed its short term liabilities ($540.5M).

Long Term Liabilities: SGRY's short term assets ($841.7M) do not cover its long term liabilities ($3.2B).


Debt to Equity History and Analysis

Debt Level: SGRY's net debt to equity ratio (124%) is considered high.

Reducing Debt: SGRY's debt to equity ratio has reduced from 266.8% to 141.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SGRY has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SGRY is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 13.4% per year.


Dividend

What is Surgery Partners's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SGRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SGRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SGRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SGRY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SGRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

J. Evans (43 yo)

1.83yrs

Tenure

US$3,541,863

Compensation

Mr. J. Eric Evans has been the Chief Executive Officer and Director of Surgery Partners, Inc. since January 13, 2020 and served as its Executive Vice President and Chief Operating Officer since April 1, 20...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD3.54M) is below average for companies of similar size in the US market ($USD5.20M).

Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SGRY's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: SGRY's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SGRY insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 76.8%.


Top Shareholders

Company Information

Surgery Partners, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Surgery Partners, Inc.
  • Ticker: SGRY
  • Exchange: NasdaqGS
  • Founded: 2004
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$3.844b
  • Shares outstanding: 87.89m
  • Website: https://www.surgerypartners.com

Number of Employees


Location

  • Surgery Partners, Inc.
  • 310 Seven Springs Way
  • Suite 500
  • Brentwood
  • Tennessee
  • 37027
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 23:20
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.